CEO Executive AssistantMergers and acquisitions are among the most consequential activities a pharma CEO undertakes. A major acquisition can transform a company’s pipeline, commercial profile, and competitive position within 12 months. A poorly executed deal can destroy years of shareholder value and distract the entire organization. Because the stakes are so high, CEOs often over-concentrate M&A activity on their personal desk, managing due diligence details, attending every workstream meeting, and making decisions that experienced M&A and business development professionals should own.
This approach is both inefficient and risk-increasing. The CEO who is embedded in due diligence detail is not spending time on the strategic judgment that only the CEO can provide: the business logic of the deal, the organizational integration vision, the board and investor communication, and the relationship with the target company’s leadership. Effective M&A delegation concentrates CEO time on these high-leverage activities while building the professional M&A and Business Development organization that executes everything else.
Strategy 1: Build a Dedicated Business Development and M&A Function
The foundation of pharma M&A delegation is having a dedicated Business Development and M&A team with the expertise and organizational authority to lead deal processes. In large pharma companies, this is a mature function with deal teams, M&A integration specialists, and licensing professionals. In smaller biotechs, it may be a VP of Business Development and a small team supported by outside advisors.
The Head of Business Development and M&A is the CEO’s primary M&A delegate. This person owns: the M&A screening and origination process, the development of deal theses and financial models, the management of the due diligence process, the coordination of all legal, financial, scientific, and commercial workstreams, and the development of the integration plan.
The CEO’s M&A role: setting the strategic priorities that guide deal screening, making the final decision on which deals to pursue, conducting the relationship with target company CEOs, reviewing and approving major deal terms, leading board and investor communication, and setting the tone for integration.
Strategy 2: Delegate Due Diligence Management to Functional Experts
Due diligence in pharmaceutical M&A covers multiple specialized domains: scientific and clinical due diligence (R&D team), regulatory due diligence (Regulatory Affairs), manufacturing and quality due diligence (Operations), commercial due diligence (Commercial), financial due diligence (Finance), legal due diligence (Legal), and IT due diligence (IT/CTO). Each workstream requires the relevant functional experts, not CEO involvement.
The CEO should not be reading due diligence reports for individual workstreams. The Head of Business Development should synthesize the full due diligence picture into an integrated assessment that surfaces the most significant risks and opportunities for CEO review. The CEO reviews the integrated assessment, asks strategic questions, and makes the risk-acceptance decision.
Individual due diligence workstream leaders are accountable to the Head of Business Development, not directly to the CEO. If the CEO is attending due diligence workstream meetings or reviewing raw due diligence data, the delegation structure is not working.
Strategy 3: Define Clear Deal Approval Authority
M&A and licensing deals span an enormous range in size, complexity, and strategic significance. A $50 million in-licensing deal for an early-stage asset requires different governance than a $5 billion acquisition. Defining approval authority by deal size and type eliminates ambiguity about when CEO and board approval are required.
A pharma M&A approval authority framework:
- Early-stage licensing and collaboration agreements up to a defined value: Head of Business Development recommends, CEO approves
- Acquisitions and significant licensing agreements above the defined threshold: CEO recommends, board approves
- Major transformational acquisitions: CEO and CFO recommend, full board approves with appropriate shareholder notification
For all deal sizes, the Head of Business Development manages the process. The difference is the approval level at which the deal is consented.
Strategy 4: Delegate Integration Planning to a Dedicated Integration Team
Integration is where M&A value is won or lost. Most deals that fail to deliver on their financial projections do so because integration was poorly planned or poorly executed, not because the deal economics were wrong. The CEO who focuses on deal origination but does not invest equally in integration governance is taking the same risk as a builder who designs a beautiful structure but does not invest in the foundation.
Establish a dedicated integration management office (IMO) for any significant acquisition. The IMO leader, who may be the Head of Business Development, a Chief Integration Officer, or a dedicated program lead, owns: the integration plan development, the cross-functional integration workstream coordination, the integration timeline and milestone tracking, and the management of integration-related communications.
The CEO’s integration role: setting the integration vision and non-negotiable principles, making decisions on significant integration resource commitments or cultural choices, communicating the integration vision to the combined organization, and reviewing integration progress through a monthly integration dashboard.
The CEO who attends every integration workstream meeting or makes every integration decision is unable to perform their other CEO responsibilities during the integration period, which can span 12 to 24 months for a major acquisition.
For context on how M&A integration connects to the supply chain and commercial delegation structures, see pharma supply chain, which addresses how supply chain integration in acquisitions can be structured within the broader operational delegation framework.
Strategy 5: Manage Target Company Relationships at the CEO Level
The one M&A activity that unambiguously belongs at the CEO level is the relationship with the target company’s CEO and senior leadership. Deal negotiations are not just financial transactions; they are relationship investments that determine whether the cultural integration will succeed.
The pharma CEO should own: the initial strategic conversation with the target CEO about deal rationale, the key negotiation conversations about deal structure and valuation at the most senior level, the communication to the target company’s board about the acquiring company’s vision for the combined organization, and the post-signing communication to the target’s employees about the integration.
These CEO relationship activities should be coordinated by the Head of Business Development, who prepares the CEO for each engagement and manages the relationship scaffolding around CEO-level interactions.
Strategy 6: Build M&A Analytics Capacity for Delegation
Effective M&A screening and deal thesis development requires strong financial modeling, market analysis, and competitive intelligence capabilities. Building this analytical capacity within the Business Development function is the prerequisite for delegating deal screening and development.
The Business Development team should own: M&A screening against defined strategic criteria, deal thesis development and financial modeling, comparable transaction analysis, and strategic scenario modeling. The CEO reviews the output of this analytical work, not the raw inputs.
When the CEO is personally building financial models or conducting market research, the Business Development function lacks the capacity to perform its job. This is an organizational capability gap, not a permanent state to be managed through CEO personal effort.
Strategy 7: Delegate M&A Communication Coordination
M&A transactions involve extensive communication management: investor relations communications (pre-announcement, announcement, and integration updates), employee communications at both the acquiring and acquired company, regulatory disclosure requirements, and media management. Coordinating all of this communication is a major operational undertaking that belongs to the Head of Communications, the Head of IR, and the General Counsel, not the CEO personally.
Define a communication workstream within the deal management structure that is owned by these functions and coordinated by the Head of Business Development. The CEO approves all significant communications (major deal announcements, investor conference presentations about the deal, employee messages) but does not draft or manage the communication logistics.
According to Harvard Business Review research on M&A communication effectiveness, M&A communication quality is one of the most significant predictors of successful integration. Professional, coordinated communication managed by dedicated communication professionals, with CEO leadership of the strategic messages, is the structure that achieves this.
See pharma CEO delegation guide for a comprehensive framework connecting M&A delegation to the full range of pharma CEO strategic and operational delegation responsibilities.
The CEO’s M&A Legacy
The M&A decisions a pharma CEO makes shape the company’s pipeline, capabilities, and competitive position for decades. The quality of those decisions depends on the CEO’s strategic clarity, risk judgment, and market perspective, not on their personal involvement in due diligence or integration project management.
Building the Business Development and M&A capability that executes complex transactions professionally, while maintaining appropriate CEO strategic oversight, is one of the most important organizational investments a pharma CEO can make. The companies that create M&A value consistently are those with strong deal teams operating with clear CEO strategic direction, not those where the CEO serves as the principal executor of every deal activity.
Related Reading
For further context, explore Delegation Strategies for Asset Management CEO and Delegation Strategies for Automotive CEO: Digital Retail.